a proapoptotic protein that drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappaB transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1. Note: This description may include information from UniProtKB.
Molecular Function: leucine zipper domain binding; protein binding; enzyme binding; protein kinase C binding; actin binding; transcription corepressor activity; protein phosphatase 1 binding
Biological Process: positive regulation of phosphoprotein phosphatase activity; actin filament bundle formation; interleukin-2 biosynthetic process; transcription, DNA-dependent; apoptosis; positive regulation of apoptosis; negative regulation of T cell receptor signaling pathway; response to lipopolysaccharide; negative regulation of B cell proliferation; negative regulation of transcription from RNA polymerase II promoter; detection of mechanical stimulus involved in sensory perception of pain; negative regulation of T cell proliferation; positive regulation of neuron apoptosis; response to wounding; response to iron(II) ion; positive regulation of action potential; detection of temperature stimulus involved in sensory perception of pain; positive regulation of amyloid precursor protein biosynthetic process
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.